Form 4: Sotera Health CEO Reports Routine Equity Transactions

Sotera Health's Chairman and CEO, Michael B. Petras Jr., reported multiple equity transactions including RSU and SAU vesting, tax withholdings, and new grants.

Summary

• Michael B. Petras Jr., Chairman and CEO of Sotera Health Co (SHC), reported several transactions on March 2, 2026, related to his equity compensation.
• He acquired 89,686 shares of Common Stock through the vesting of performance-based Share Appreciation Units (SAUs) granted on March 3, 2025.
• He was granted 240,248 Restricted Stock Units (RSUs) and 120,124 Share Appreciation Units (SAUs) on March 2, 2026, with a grant price of $0.
• A total of 190,297 shares of Common Stock were disposed of at a price of $15.91 per share to satisfy tax withholding obligations related to the vesting of various RSUs and SAUs.
• Following these transactions, Mr. Petras directly beneficially owns 692,427 shares of Common Stock and indirectly owns 4,819,393 shares through a Grantor Trust.
• He also directly owns 59,790 Share Appreciation Units and 120,124 newly granted Share Appreciation Units.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as slightly positive, reflecting routine executive compensation activities. The vesting of performance-based units and new grants indicate ongoing management alignment and retention, which are generally favorable, though the transactions themselves are not market-moving events.

Positives

• The vesting of 89,686 performance-based SAUs indicates that performance conditions were met, aligning management incentives with company success.
• The grant of 240,248 RSUs and 120,124 SAUs on March 2, 2026, demonstrates ongoing commitment to executive compensation and retention, linking future performance to equity value.
• The new RSU and SAU grants include future vesting schedules (60%, 20%, 20% installments commencing March 2027), providing a long-term incentive for the CEO.

Negatives

• A total of 190,297 shares were disposed of to cover tax withholding obligations, which reduces the direct beneficial ownership of the CEO, although this is a standard practice for equity compensation.

Risks

• The value of the equity compensation (RSUs and SAUs) is subject to the future stock price of Sotera Health Co, exposing the CEO's compensation to market fluctuations.
• Future vesting of SAUs is subject to stock price-related performance conditions, meaning the full potential value may not be realized if performance targets are not met.

Future Outlook

The filing indicates future vesting events for the CEO's equity awards. RSUs and SAUs granted on March 2, 2026, will generally vest annually in 60%, 20%, and 20% installments, commencing March 2027. Remaining SAUs from the March 3, 2025, grant are scheduled to vest annually in equal installments in March 2027 and March 2028, subject to performance conditions.

Industry Context

StockSavvy.ai notes that this Form 4 filing is a routine disclosure of insider transactions, specifically related to executive compensation. It does not provide broader industry trends or competitive analysis but reflects standard practices for incentivizing and retaining key management within publicly traded companies in the healthcare or sterilization services sector.

Stakeholder Impact

• Shareholders: The transactions demonstrate ongoing alignment of the CEO's interests with shareholder value through equity-based compensation, subject to vesting and performance conditions.
• Employees: The compensation structure for the CEO may reflect broader company-wide incentive programs, potentially influencing employee morale and retention strategies.

Next Steps

• Future vesting of RSUs and SAUs granted on March 2, 2026, with installments commencing March 2027.
• Future vesting of remaining SAUs from the March 3, 2025, grant in March 2027 and March 2028, subject to performance.

Key Dates

Keywords

Sotera Health, SHC, Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Share Appreciation Units, CEO, Stock Vesting, Tax Withholding